NUWE Quote, Financials, Valuation and Earnings

Hologic has a net margin of 99.62% compared to Nuwellis's net margin of 18.08%. Nuwellis's return on equity of -918.02% beat Hologic's return on equity of 16.05%.

Nuwellis has a consensus price target of --, signalling upside risk potential of 1500%. On the other hand Hologic has an analysts' consensus of $85.85 which suggests that it could grow by 19.82%. Given that Nuwellis has higher upside potential than Hologic, analysts believe Nuwellis is more attractive than Hologic.

Nuwellis has a beta of 0.315, which suggesting that the stock is 68.488% less volatile than S&P 500. In comparison Hologic has a beta of 0.958, suggesting its less volatile than the S&P 500 by 4.165%.

Nuwellis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hologic offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuwellis pays -- of its earnings as a dividend. Hologic pays out -- of its earnings as a dividend.

Nuwellis quarterly revenues are $2.4M, which are smaller than Hologic quarterly revenues of $988M. Nuwellis's net income of $2.4M is lower than Hologic's net income of $178.6M. Notably, Nuwellis's price-to-earnings ratio is -- while Hologic's PE ratio is 21.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuwellis is 0.06x versus 4.22x for Hologic. Usually stocks with elevated PS ratios are considered overvalued.

Singular Genomics Systems has a net margin of 99.62% compared to Nuwellis's net margin of -4136.7%. Nuwellis's return on equity of -918.02% beat Singular Genomics Systems's return on equity of -54.24%.

Nuwellis has a consensus price target of --, signalling upside risk potential of 1500%. On the other hand Singular Genomics Systems has an analysts' consensus of -- which suggests that it could fall by -36.8%. Given that Nuwellis has higher upside potential than Singular Genomics Systems, analysts believe Nuwellis is more attractive than Singular Genomics Systems.

Nuwellis has a beta of 0.315, which suggesting that the stock is 68.488% less volatile than S&P 500. In comparison Singular Genomics Systems has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Nuwellis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Singular Genomics Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuwellis pays -- of its earnings as a dividend. Singular Genomics Systems pays out -- of its earnings as a dividend.

Nuwellis quarterly revenues are $2.4M, which are larger than Singular Genomics Systems quarterly revenues of $406K. Nuwellis's net income of $2.4M is higher than Singular Genomics Systems's net income of -$16.8M. Notably, Nuwellis's price-to-earnings ratio is -- while Singular Genomics Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuwellis is 0.06x versus 18.34x for Singular Genomics Systems. Usually stocks with elevated PS ratios are considered overvalued.

Quanterix has a net margin of 99.62% compared to Nuwellis's net margin of -27.76%. Nuwellis's return on equity of -918.02% beat Quanterix's return on equity of -11.45%.

Nuwellis has a consensus price target of --, signalling upside risk potential of 1500%. On the other hand Quanterix has an analysts' consensus of $21.80 which suggests that it could grow by 107.42%. Given that Nuwellis has higher upside potential than Quanterix, analysts believe Nuwellis is more attractive than Quanterix.

Nuwellis has a beta of 0.315, which suggesting that the stock is 68.488% less volatile than S&P 500. In comparison Quanterix has a beta of 1.300, suggesting its more volatile than the S&P 500 by 29.975%.

Nuwellis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quanterix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuwellis pays -- of its earnings as a dividend. Quanterix pays out -- of its earnings as a dividend.

Nuwellis quarterly revenues are $2.4M, which are smaller than Quanterix quarterly revenues of $34.1M. Nuwellis's net income of $2.4M is higher than Quanterix's net income of -$9.5M. Notably, Nuwellis's price-to-earnings ratio is -- while Quanterix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuwellis is 0.06x versus 3.12x for Quanterix. Usually stocks with elevated PS ratios are considered overvalued.

Varex Imaging has a net margin of 99.62% compared to Nuwellis's net margin of -24.31%. Nuwellis's return on equity of -918.02% beat Varex Imaging's return on equity of -8.23%.

Nuwellis has a consensus price target of --, signalling upside risk potential of 1500%. On the other hand Varex Imaging has an analysts' consensus of -- which suggests that it could grow by 57%. Given that Nuwellis has higher upside potential than Varex Imaging, analysts believe Nuwellis is more attractive than Varex Imaging.

Nuwellis has a beta of 0.315, which suggesting that the stock is 68.488% less volatile than S&P 500. In comparison Varex Imaging has a beta of 0.603, suggesting its less volatile than the S&P 500 by 39.736%.

Nuwellis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Varex Imaging offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuwellis pays -- of its earnings as a dividend. Varex Imaging pays out -- of its earnings as a dividend.

Nuwellis quarterly revenues are $2.4M, which are smaller than Varex Imaging quarterly revenues of $205.7M. Nuwellis's net income of $2.4M is higher than Varex Imaging's net income of -$50M. Notably, Nuwellis's price-to-earnings ratio is -- while Varex Imaging's PE ratio is 17.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuwellis is 0.06x versus 0.72x for Varex Imaging. Usually stocks with elevated PS ratios are considered overvalued.